Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DYANAVEL XR 20 vs ADDERALL 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DYANAVEL XR is a central nervous system (CNS) stimulant. The mode of action is primarily through blockade of the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space. It also releases these monoamines from storage sites. The dextroamphetamine component is more potent than amphetamine in inhibiting norepinephrine reuptake, while the amphetamine component is more potent in inhibiting dopamine reuptake.
Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
FDA-approved: Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older.,Off-label: Treatment-resistant depression, narcolepsy (though individual components are approved for narcolepsy, DYANAVEL XR as a specific formulation is not).
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Initial 20 mg orally once daily in the morning, with or without food; may increase by 10 mg weekly to maximum 60 mg/day.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.
Terminal elimination half-life: 6-8 hours (stable metabolite). Clinical context: Twice-daily dosing typical due to pharmacokinetic profile; extended half-life compared to immediate-release amphetamine.
Immediate-release: 9–11 hours (mean 10 hours for dextroamphetamine); extended-release: 10–13 hours. Terminal half-life may be prolonged with urinary p H >7.
Amphetamine is metabolized primarily by CYP2D6 and also by CYP2C19 and CYP3A4 via deamination, oxidation, and conjugation. The active metabolites include 4-hydroxyamphetamine and norephedrine. Genetic polymorphisms in CYP2D6 may affect metabolism and drug levels.
Amphetamine is metabolized via CYP2D6, with deamination and oxidation as major pathways.
Renal: 90% (unchanged drug and metabolites, primarily hippuric acid). Fecal/biliary: <1%.
Renal (90% as unchanged drug and metabolites; ~30% unchanged), minor fecal elimination (<5%).
15-40% bound to albumin.
~16% bound to plasma proteins (primarily albumin).
3-5 L/kg (indicates extensive tissue distribution; crosses blood-brain barrier).
3.5–4.5 L/kg; indicates extensive tissue distribution (e.g., brain, lungs).
Oral (extended-release): 95% (high bioavailability; minimal first-pass metabolism).
Oral immediate-release: 96–100% (first-pass metabolism minimal); extended-release: approximately 96% relative to immediate-release.
GFR 15-29 m L/min: maximum 40 mg/day; GFR <15 m L/min or dialysis: not recommended.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: use maximum of 50% of usual dose; not recommended in ESRD.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Ages 6-17: initial 10 mg once daily; may increase by 5-10 mg weekly to max 30 mg/day for ages 6-12, max 40 mg/day for ages 13-17.
Children 3-5 years: initial 2.5 mg daily, increase by 2.5 mg weekly; max 40 mg/day. Children ≥6 years: initial 5 mg once or twice daily, increase by 5 mg weekly; max 40 mg/day (or 20 mg/day for extended-release).
Initiate at 10 mg once daily; lower doses may be required due to renal function decline; monitor for cardiac effects.
Initiate at 2.5 mg once or twice daily; increase by 2.5-5 mg weekly; monitor for cardiovascular effects and confusion.
DYANAVEL XR has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular events. It should be prescribed cautiously, especially in patients with a history of substance abuse.
Adderall has a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Serious cardiovascular events: Sudden death, stroke, and myocardial infarction have been reported, especially in patients with structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase: Monitor vital signs regularly.,Psychiatric adverse events: May exacerbate pre-existing psychosis, mania, or aggression; caution in patients with bipolar disorder or history of psychosis.,Seizures: May lower seizure threshold; use cautiously in patients with seizure disorders.,Peripheral vasculopathy: Including Raynaud's phenomenon; monitor for digital changes.,Serotonin syndrome: Risk when co-administered with serotonergic drugs.,Growth suppression: Long-term use may slow growth in children; monitor height and weight.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Blood pressure and heart rate increases,Psychiatric adverse events such as psychosis or mania,Growth suppression in pediatric patients,Seizures,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome when co-administered with serotonergic drugs
Hypersensitivity to amphetamine or any component of the formulation.,Concurrent use or within 14 days of monoamine oxidase inhibitors (MAOIs) due to risk of hypertensive crisis.,Hyperthyroidism.,Agitated states.,Glaucoma.,History of drug abuse.,Cardiovascular disease: Moderate to severe hypertension, advanced arteriosclerosis, symptomatic coronary artery disease, structural heart abnormalities, cardiomyopathy, serious arrhythmias, or other serious cardiac conditions.
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,Concurrent use of MAOIs or within 14 days of discontinuing MAOI,Hypersensitivity to amphetamine products
Avoid high-fat meals around the time of administration as they may delay absorption and reduce peak concentration. Limit caffeine intake (coffee, tea, soda, energy drinks) as it can exacerbate nervousness, insomnia, and cardiovascular effects. No specific food restrictions otherwise.
Avoid acidic foods or vitamin C supplements within 1 hour of dosing as they decrease absorption. Grapefruit may increase drug levels. Caffeine and other stimulants should be limited. Avoid alcohol. High-fat meals may delay onset but not overall absorption.
Pregnancy Category C. There is no adequate and well-controlled study in pregnant women. In animal reproduction studies, amphetamine (dextroamphetamine/amphetamine) at doses up to 41 times the maximum recommended human dose of 20 mg/day (based on mg/m²) produced no teratogenic effects; however, increased neonatal mortality and reduced growth were observed at maternally toxic doses. In humans, retrospective studies have reported a higher incidence of premature delivery, low birth weight, and withdrawal symptoms (e.g., dysphoria, agitation, lassitude) in neonates exposed to amphetamines during the third trimester. There is also a potential risk for cardiovascular malformations if used in the first trimester. Therefore, the drug should be used only if the potential benefit justifies the potential risk to the fetus.
Pregnancy Category C (pre-2015) / Not assigned under current FDA labeling. First trimester: Studies suggest a possible small increased risk of congenital malformations, particularly cardiovascular defects and oral clefts, but absolute risk is low. Second and third trimesters: Exposure may increase risk of preterm delivery, low birth weight, and neonatal withdrawal symptoms including irritability, dysphoria, and feeding difficulties. Chronic use may lead to fetal growth restriction.
Amphetamines are excreted into human milk. The milk-to-plasma concentration ratio for amphetamine is approximately 1.8 to 5.9. A nursing infant would receive 4-10% of the maternal weight-adjusted dose. There are reports of irritability, poor feeding, and decreased weight gain in infants exposed to amphetamines via breast milk. The manufacturer recommends discontinuing nursing or the drug, taking into account the importance of the drug to the mother.
Amphetamine is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2.0–3.0. Relative infant dose is estimated at 5–10% of the maternal weight-adjusted dose. Use while breastfeeding is generally not recommended due to potential adverse effects on the infant, including irritability, poor feeding, and insomnia. Consider alternative treatments or discontinue breastfeeding.
Pregnancy may alter the pharmacokinetics of amphetamines due to increased plasma volume, renal blood flow, and hepatic metabolism. The elimination half-life may be shortened, requiring dose adjustments. However, no specific dosing guidelines are established for pregnancy. Use the lowest effective dose, and monitor clinical response and tolerability. Postpartum doses may need to be reduced to pre-pregnancy levels.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism, and increased renal clearance) can lower amphetamine plasma concentrations. Dose adjustments may be necessary to maintain therapeutic effect; however, formal guidelines are lacking. Use the lowest effective dose and monitor clinical response. Avoid during pregnancy unless potential benefits outweigh risks.
For patients with attention deficit hyperactivity disorder (ADHD), initiate at 20 mg once daily in the morning; may increase by 10 mg weekly to a maximum of 60 mg/day. Contains immediate-release and extended-release beads; avoid crushing or chewing. Monitor for hypertension, tachycardia, and growth suppression in children. Use with caution in patients with pre-existing cardiovascular disease or seizure disorder. Do not co-administer with MAOIs or within 14 days of discontinuing an MAOI.
ADDERALL 5 (amphetamine/dextroamphetamine) is a CNS stimulant. Note that 5 mg is a low starting dose; titrate based on response and tolerability. Avoid use in patients with structural cardiac abnormalities, glaucoma, hyperthyroidism, or history of drug abuse. Monitor for hypertension, tachycardia, and psychiatric symptoms. Can worsen tics or Tourette syndrome. Use with caution with MAOIs (risk of hypertensive crisis).
Take exactly as prescribed, usually once daily in the morning to avoid insomnia.,Swallow capsules whole; do not crush, chew, or open them.,Avoid alcohol and caffeine-containing products as they may worsen side effects.,Inform your doctor of all other medications, including over-the-counter drugs and supplements.,Report any chest pain, shortness of breath, or fainting immediately.,For children, height and weight will be monitored during treatment.,Do not stop abruptly without consulting your doctor; dosage may need to be tapered.
Take exactly as prescribed; do not increase dose without consulting doctor.,Swallow tablet whole; do not crush or chew.,Avoid taking late in the day to prevent insomnia.,May cause dizziness; avoid driving if affected.,Report chest pain, shortness of breath, or fainting.,May be habit-forming; do not share with others.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DYANAVEL XR 20 vs ADDERALL 5, answered by our medical review team.
DYANAVEL XR 20 is a CNS Stimulant that works by DYANAVEL XR is a central nervous system (CNS) stimulant. The mode of action is primarily through blockade of the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space. It also releases these monoamines from storage sites. The dextroamphetamine component is more potent than amphetamine in inhibiting norepinephrine reuptake, while the amphetamine component is more potent in inhibiting dopamine reuptake.. ADDERALL 5 is a CNS Stimulant that works by Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DYANAVEL XR 20 and ADDERALL 5 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DYANAVEL XR 20 is: Initial 20 mg orally once daily in the morning, with or without food; may increase by 10 mg weekly to maximum 60 mg/day.. The standard adult dose of ADDERALL 5 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DYANAVEL XR 20 and ADDERALL 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DYANAVEL XR 20 is classified as Category C. Pregnancy Category C. There is no adequate and well-controlled study in pregnant women. In animal reproduction studies, amphetamine (dextroamphetamine/amphetamine) at doses up to 4. ADDERALL 5 is classified as Category C. Pregnancy Category C (pre-2015) / Not assigned under current FDA labeling. First trimester: Studies suggest a possible small increased risk of congenital malformations, particularl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.